{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Frediani JK"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","NIBIB NIH HHS","National Institute of Biomedical Imaging and Bioengineering"],"pagination":["14604"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8285474"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings as \"self-tests\". Multidisciplinary evaluation of the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW, a widely used rapid antigen test, included limit of detection, variant detection, test performance across different age-groups, and usability with self/caregiver-administration. While BinaxNOW detected the highly infectious variants, B.1.1.7 (Alpha) first identified in the UK, B.1.351 (Beta) first identified in South Africa, P.1 (Gamma) first identified in Brazil, B.1.617.2 (Delta) first identified in India a"],"journal":["Scientific reports"],"pubmed_title":["Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration."],"pmcid":["PMC8285474"],"funding_grant_id":["UL1 TR002378","U54 EB027690 02S1","U54 EB027690"],"pubmed_authors":["O'Neal JW","Gonzalez MD","Sullivan J","Martin GS","Lam WA","Roback JD","Stone C","Rao A","Esper A","Mavigner M","Rebolledo PA","Bassit L","Jerris R","Kempker RR","Rogers BB","Morris CR","Le K","Nehl EJ","Frediani JK","Ramachandra T","Washington C","Vos MB","Wood A","Wang YF","Foster A","Levy JM","Schoof N","Waggoner JJ","Farmer S","Schinazi RF","Tyburski EA","Van Leung-Pineda","Figueroa J","Chahroudi A","Suessmith A","Cordero MC"],"additional_accession":[]},"is_claimable":false,"name":"Multidisciplinary assessment of the Abbott BinaxNOW SARS-CoV-2 point-of-care antigen test in the context of emerging viral variants and self-administration.","description":"While there has been significant progress in the development of rapid COVID-19 diagnostics, as the pandemic unfolds, new challenges have emerged, including whether these technologies can reliably detect the more infectious variants of concern and be viably deployed in non-clinical settings as \"self-tests\". Multidisciplinary evaluation of the Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW, a widely used rapid antigen test, included limit of detection, variant detection, test performance across different age-groups, and usability with self/caregiver-administration. While BinaxNOW detected the highly infectious variants, B.1.1.7 (Alpha) first identified in the UK, B.1.351 (Beta) first identified in South Africa, P.1 (Gamma) first identified in Brazil, B.1.617.2 (Delta) first identified in India a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-04T23:27:00.203Z","creation":"2022-02-10T20:36:37.202Z"},"accession":"S-EPMC8285474","cross_references":{"pubmed":["34272449"],"doi":["10.1038/s41598-021-94055-1"]}}